Discovery could lead to new therapies for diabetics

January 12, 2018, Mount Desert Island Biological Laboratory
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy also plays a role in peripheral neuropathy caused by diabetes. The significance of the identification of a common molecular mechanism is that the drug candidates she identified to treat chemotherapy-induced peripheral neuropathy could potentially be used to treat peripheral neuropathy caused by diabetes as well. Peripheral neuropathy is a potentially disabling condition affecting up to 40 million Americans that causes, pain, tingling and numbness in the hands and feet. Treatments exist for alleviating pain, but the development of treatments to prevent or reverse nerve degeneration has been stalled by a lack of understanding of the underlying mechanisms. Credit: MDI Biological Laboratory

New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy also plays a role in peripheral neuropathy caused by diabetes.

The significance of the identification of a common molecular mechanism is that many more patients could potentially benefit from drugs that target this mechanism. In earlier research, Rieger identified two for the treatment of chemotherapy-induced that she is seeking to move into human clinical trials.

Peripheral neuropathy is a potentially disabling condition affecting up to 40 million Americans that causes, pain, tingling and numbness in the hands and feet. Treatments exist for alleviating pain, but the development of treatments to prevent or reverse nerve degeneration has been stalled by a lack of understanding of the underlying mechanisms.

"This finding means that the drug candidates we have identified to treat chemotherapy-induced peripheral neuropathy could potentially be used to treat peripheral neuropathy that is caused by diabetes as well," Rieger said.

Diabetes affects an estimated 28 million people in the United States and over 300 million worldwide, 50 to 60 percent of whom suffer from peripheral neuropathy. That number is expected to double in the coming decades as a result of the fact that diabetes is approaching epidemic proportions worldwide.

About 450,000 people in the United States suffer from peripheral neuropathy caused by , the second leading cause of the condition.

"Peripheral neuropathy is a major and growing health problem," said Kevin Strange, Ph.D., president of the MDI Biological Laboratory. "The identification of the mechanism underlying glucose-induced peripheral neuropathy means that millions of patients could potentially benefit from the development of drugs that influence this pathway."

In previous research in zebrafish, Rieger identified two compounds that prevent and reverse peripheral neuropathy caused by exposure to Taxol, or paclitaxel, a common cancer chemotherapy agent. The compounds are the subject of a pending patent originally filed in 2016 by the MDI Biological Laboratory.

The recent study, published in theJournal of Diabetes and Its Complications, tested the effectiveness of one of these compounds in preventing glucose-induced peripheral neuropathy. The study found the compound to be effective in zebrafish and in mice, which are mammals like humans.

"The fact that this compound works in two such disparate species makes it more likely it will work in humans too," Rieger noted.

The research in mice was conducted in collaboration with Kristy Townsend, Ph.D., an assistant professor of neurobiology at the University of Maine. The mice were fed a high fat/high sugar diet in order to induce diabetes.

In her previous research on chemotherapy-induced peripheral neuropathy, Rieger linked the development of peripheral neuropathy in the zebrafish tailfin, which is analogous to a human extremity, to an increase in MMP-13 (matrix metalloproteinase-13), an enzyme that breaks down the collagen or "glue" that binds skin cells together.

Rieger believes this breakdown leads to the degeneration of the long, threadlike that innervate the skin. The degeneration of these nerve endings, which convey sensory information like temperature, pain and mechanical stimulation to the central nervous system, is responsible for the symptoms of peripheral neuropathy.

In the recent study of glucose-induced peripheral neuropathy, Rieger found that the same pathway is involved. She also found that reactive oxygen species (ROS), which can cause tissue damage, play a role in the process. The formation of ROS, which (also known as oxidative stress) is a hallmark of diabetes.

Rieger found that ROS are the cause of the increased MMP-13 activity, and that increased MMP-13 activation and nerve damage can be prevented by the pharmacological inhibition of ROS with an anti-oxidant compound.

One of the goals of the study was to develop a zebrafish model to study glucose-induced peripheral neuropathy. Rieger will use the new model to delve more deeply into the mechanisms underlying glucose-induced peripheral and to identify more effective variants of the drug candidates she has discovered.

Larval zebrafish are used as a model because their translucency allows scientists to easily track nerve degeneration in live animals.

Explore further: Scientist identifies mechanism underlying peripheral neuropathy

More information: Ashley L. Waldron et al. Oxidative stress-dependent MMP-13 activity underlies glucose neurotoxicity, Journal of Diabetes and its Complications (2017). DOI: 10.1016/j.jdiacomp.2017.11.012

Related Stories

Scientist identifies mechanism underlying peripheral neuropathy

April 14, 2016
Recent research by Sandra Rieger, Ph.D., of the MDI Biological Laboratory identifying the underlying mechanisms of peripheral neuropathy, or nerve damage, has raised the prospect that drug therapies can be developed for the ...

Discovery of peripheral neuropathy cause suggests potential preventive measures

October 11, 2017
In discovering how certain chemotherapy drugs cause the nerve damage known as peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side ...

Potential new drug therapy for peripheral nerve damage announced

February 22, 2016
The Mount Desert Island (MDI) Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, ...

Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment

May 13, 2016
Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients ...

Autonomic neuropathy after chemotherapy—is it permanent?

February 22, 2017
Dear Mayo Clinic: After six months of chemotherapy, I developed autonomic neuropathy. I have been done with chemotherapy for a few months, but the neuropathy has not gone away. Is there a chance it could be permanent?

Study finds cold therapy may be effective at controlling cancer treatment side effects

October 12, 2017
A new study published in the Journal of the National Cancer Institute finds that cryotherapy, specifically having chemotherapy patients wear frozen gloves and socks for 90-minute periods, is useful for preventing symptoms ...

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Scientists identify method to study resilience to pain

December 14, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

Parents' brain activity 'echoes' their infant's brain activity when they play together

December 13, 2018
When infants are playing with objects, their early attempts to pay attention to things are accompanied by bursts of high-frequency activity in their brain. But what happens when parents play together with them? New research, ...

In the developing brain, scientists find roots of neuropsychiatric diseases

December 13, 2018
The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.